Skip to main content

Table 1 Baseline characteristics of the patients included in study (n = 437)

From: Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study)

Variable N = 437
Sex  
   Male (n(%)) 239 (54.7)
   Female (n(%)) 198 (45.3)
Age (years)* 54.7 ± 12.1
Body mass index (kg/m2) 28.8 ± 4.6
Diabetes (n(%)) 125 (28.7)
Fasting plasma glucose (mM/l)* 5.2 ± 0.6
Family history of dyslipidemia (n(%)) 171 (39.2)
Coronary heart disease (n(%)) 196 (45)
Aspartate aminotranferase (mU/l) 23 ± 11
Alanine aminotransferase (mU/l) 26 ± 14
  1. Data expressed as mean ± standard deviation. *To convert to mg/dl, multiply by 18